Ponalrestat

This classification denotes an aldose reductase inhibitor with the molecular formula C17H12BrFN2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2CV0A5G64E, chemically known as 3-(4-bromo-2-fluorobenzyl)-3,4-dihydro-4-oxo-1-phthalazineacetic acid but generally known as ponalrestat, which bears US NIH Compound Identifier 5278. European Medicines Agency schedules Ponalrestat in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09978MIG. The term PONALRESTAT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 2, No. 3, 1988, List 28). PONALRESTAT is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ponalrestat under HS 29339990 and SITC 51577. As of Q4 2014, PONALRESTAT remains the US FDA Preferred Term for this commodity. Ponalrestat bears US NLM identifiers UMLS ID C0071716 and NCI Concept Code C82173. SMILES: BRC1CC(F)C(CN2NC(C3C(C2=O)CCCC3)CC(=O)O)CC1.